Corcept Therapeutics Inc (CORT) saw an uptrend of 966997% in the recent trading with $1700000.0 being its most recent. The current price level -36.69% lower than the highest price of $117.33 marked by the stock while trading over the past 52-weeks, whereas it is 154.56% higher than the lowest price of $29.18 the company dropped to over past 52-weeks. The latest news story on CORT appeared in (Business Wire) under the title “Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care” on Today.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 4 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.00 for the stock.
Corcept Therapeutics Inc Earnings – What Happened With CORT
Coming around sales and income figures on CORT Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Corcept Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 105.98 million. CORT does have institutional investors; and they hold 78.88% of the stock.
As on 2024-06-30, BLACKROCK INC. was the top most holder in Corcept Therapeutics Inc (NASDAQ:CORT) with an ownership of 16.54 million shares of the company or 16.0391 of the stake worth $537.36 million. The filing also reveals VANGUARD GROUP INC as the second largest holder in the company with a control over 9.2648 of the outstanding shares. Its stake is worth $310.4 million for having 9.55 million shares in hand.
INGALLS & SNYDER LLC also came holding a key position in the company during the recent quarter and it now holds 7.989 of the outstanding shares. With this there are now 552.0 institutions which have possession in CORT’s shares.
Key Metrics forCORT
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Corcept Therapeutics Inc has a debt to equity ratio of 0.01.
Technical Analysis of Corcept Therapeutics Inc (NASDAQ:CORT) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Corcept Therapeutics Inc (CORT), we notice that the stock’s 20-day average volume is at 1,437,575 shares and 100% of short term indicators are suggesting the stock as Buy. Medium term indicators at an average of 100% are spotting the stock at Buy with its 50-day average volume of 1,341,472 shares. And to end, CORT’s 100-day average volume is 1,484,075 shares with 100% of the long-term indicators pointing towards Buy for the stock.
